Judge Rejects Novartis’ Request to Speed Up Hearing in 340B Contract Pharmacy Lawsuit

A federal judge yesterday denied drug maker Novartis’ request to speed up a hearing on its request that the judge block the government from punishing the company over its denials of 340B pricing when health care providers use contract pharmacies

A federal judge yesterday denied drug maker Novartis’ request to speed up a hearing on its request that the judge block the government from punishing the company over its denials of 340B pricing when health care providers use contract pharmacies.

Read More »

News Alert: New Senate Bill Would Let HRSA Audit 340B Providers to See How They Use 340B Net Income

Senator Mike Braun (R-IN) has introduced legislation to let the government audit 340B entities to determine how they use net income from 340B savings.

U.S. Sen. Mike Braun (R-Ind.) introduced legislation last night to let the federal government audit 340B covered entities to determine how they use net income from drugs bought under the 340B program.

Please Login or Become

Read More »

Starting Next Month, HRSA Plans to Audit Some 340B Entities Onsite for First Time Since Pandemic

HRSA says it may resume some onsite audits of 340B covered entities as early as next month, sparking concerns among some providers already battling the fallout from the Delta variant of COVID-19.

The U.S. Health Resources and Services Administration (HRSA) says it plans to resume some onsite 340B compliance audits of covered entities starting in October.

Please Login or Become a Paid Subscriber to View this Content

Read More »

House GOP Conference Chair Stefanik Signs on to 340B Anti-Pickpocketing Bill

House Republican conference chair Elise Stefanik (R-NY) is the most high profile sponsor of date for the bipartisan 340B Protect Act.

U.S. House GOP Conference Chair Elise Stefanik (N.Y.), the third highest-ranking House Republican, has issued a news release and tweeted about signing on as a sponsor of bipartisan legislation prohibiting pharmacy benefit managers (PBMs) and other third-party payers from paying

Read More »

HHS Is Vetting OPA Director Applications and Apexus Is Seeking a New Senior VP For High-Profile Position

HRSA and its 340B government contractor are looking to fill two critically important positions including replacing Rear Admiral Krista Pedley who has recently been promoted from her position as OPA Director.

The federal government has started reviewing applications from individuals seeking to be the next Director of the U.S. Health Resources and Services Administration (HRSA) Office of Pharmacy Affairs (OPA), the unit within HRSA that oversees the 340B program. Tuesday, Sept.

Read More »

Biden Picks Academic with Hospital Connections to Run HHS Policy Shop

Robert Otto Valdez has been selected by President Biden for a key HHS policy position that impacts the 340B program.

President Biden announced last week that he plans to nominate public health expert Robert Otto Valdez to serve as U.S. Health and Human Services (HHS) Assistant Secretary for Planning and Evaluation (ASPE).

Please Login or Become

Read More »

House GOP Effort to Amend 340B Falls Short in Key Committee

U.S. House Energy & Commerce Republicans yesterday filed, but majority Democrats did not consider, four 340B-related amendments to crucial budget legislation.

U.S. House Energy & Commerce Republicans yesterday filed, but majority Democrats did not consider, four 340B-related amendments to budget legislation integral to enacting congressional Democrats and the Biden administration’s Build Back Better plan.

Please Login or

Read More »

In His First Public Comments, Ex-HHS Top Lawyer Stands by 340B Contract Pharmacy Advisory Opinion

Ex-HHS General Counsel Robert Charrow during a webinar yesterday defended his since-withdrawn 340B contract pharmacy advisory opinion.

Former U.S. Health and Human Services Department General Counsel Robert Charrow yesterday defended his strongly worded and colorful December 2020 advisory opinion, since vacated by a court and withdrawn by HHS, that the 340B statute unambiguously requires drug manufacturers to

Read More »

Divisions Among 340B Provider, Manufacturer, and Oncology Stakeholders on Stark Display During Webinar

Champions for 340B health centers and hospitals on one side and drug manufacturers and oncologists in private practice on the other faced off yesterday during a webinar on 340B hosted by STAT.

Champions for safety-net health care providers on one side and drug manufacturers and oncologists in private practice on the other faced off yesterday during a health care news service’s webinar on the 340B program.

Please Login

Read More »

340B Hospitals and Independent Oncologists Issue Dueling Reports on Drug Discount Program

340B hospitals and oncologists working in private practice have issued dueling reports about who profits unjustly in connection with the drug discount program.

Hospitals in the 340B program and oncologists working in private practice have issued dueling reports about who profits unjustly in connection with the drug discount program.

Please Login or Become a Paid Subscriber to View this

Read More »
Generic selectors
Exact matches only
Search in title
Search in content